ABOUT RISEN
Risen Group
Corporate Culture
Development History
R&D Manangement Team
Partners
R&D
PIPELINE
CLINICAL
RP901
RP902
RP903
NEWS
Company news
IP granted
Publications
CONTACT US
CAREERS
Working at Risen
Job opportunities
Employee welfare
繁体
简体
RISEN PHARMA
ABOUT RISEN
Risen Group
Corporate Culture
Development History
Management Team
Partners
R&D
PIPELINE
CLINICAL
RP901
RP902
RP903
NEWS
Company news
IP granted
Publications
CONTACT US
CAREERS
Working at Risen
Job opportunities
Employee welfare
Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”
Release time：2023-04-10 Click：488
Hot News
Congratulations to Risen for being listed on the "Hurun Global Cheetahs Index 2024"
Congratulations to Risen and its chairman Jiasheng Lv, Ph.D. for being listed on the （Baoding International Medical Base · Hurun China Healthcare Pioneering Young Start-ups 2024）and（Baoding International Medical Base ·
PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.
Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.
Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved
沪ICP备16020731号-1
Design by：
yushangweb
